TRPV1 Inhibitors
1 drugsAbout TRPV1
TRPV1 (transient receptor potential vanilloid 1) is a nonselective cation channel primarily expressed on sensory neurons. It integrates noxious stimuli, playing a crucial role in pain and temperature sensation. TRPV1 is activated by heat, protons (acid), and capsaicin.
TRPV1 is a target for pain management due to its involvement in pain pathways. Currently, there is no genetic evidence directly linking TRPV1 to specific diseases. Its role in pain signaling makes it a compelling target for novel analgesics.
TRPV1 is targeted by one FDA-approved drug, QUTENZA, a small molecule with three indications. AVERITAS is the sole company with an approved TRPV1-targeting drug in the pain therapeutic area.
Top TRPV1 Drugs
The competitive landscape is highly concentrated, with AVERITAS being the only company with an approved drug.
The lack of competition may present an opportunity for new market entrants.
TRPV1 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets TRPV1, using small molecule modality.
Exploring alternative modalities like antibodies or peptides could create differentiation.
TRPV1 Clinical Trials 66 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on TRPV1. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 17 | 16 | 0 | 1 | 100% |
| Phase 2 | 17 | 12 | 4 | 1 | 75% |
| Phase 3 | 15 | 9 | 3 | 3 | 75% |
| Phase 4 | 17 | 14 | 2 | 1 | 88% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
TRPV1 Drug Approval Timeline (2009 - 2009)
The first and only drug, QUTENZA, was approved in 2009.
The stagnant approval timeline suggests potential saturation or challenges in developing new TRPV1-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 50 (12 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on TRPV1. A trial counts if an approved drug acting on TRPV1 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.